Precigen 2025 Full Year Financial Results & Business Update: Detailed Investor Report
Precigen Reports Full Year 2025 Financial Results and Major Business Milestones
Transformation to Commercial Stage Company with PAPZIMEOS Launch
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in precision medicines, has delivered a pivotal update for investors, marking its transition from a clinical-stage to a commercial-stage company in 2025. This transformation was catalyzed by the US Food and Drug Administration’s (FDA) full approval of PAPZIMEOS™ (zopapogene imadenovec-drba) in August 2025, the first and only FDA-approved treatment for adults with Recurrent Respiratory Papillomatosis (RRP).
Key Highlights and Developments
- PAPZIMEOS Launch: The commercial rollout began in August 2025, generating \$3.4 million in net product revenue in Q4 2025, its first partial quarter. Demand is rising sharply in Q1 2026, signaling strong physician adoption and patient uptake nationwide.
- Market Acceptance & Coverage: The product is now prescribed across major medical centers and community practices, with patient hub enrollment surpassing 300 patients. Payer coverage now extends to approximately 215 million insured US lives, including Medicare, Medicaid, and a majority of leading private insurers, representing about 90% of insured lives.
- Regulatory Milestones: The Centers for Medicare and Medicaid Services assigned a permanent J-code (J3404) to PAPZIMEOS, effective April 1, 2026, streamlining reimbursement and potentially accelerating patient access.
- European Progress: The Marketing Authorization Application (MAA) for PAPZIMEOS is validated and under review by the European Medicines Agency, with orphan drug designation granted by the European Commission.
- Clinical Evidence & Consensus: An expert consensus paper published in January 2026—authored by 16 leading RRP physicians and sponsored by the Recurrent Respiratory Papillomatosis Foundation—formally recommends PAPZIMEOS as the new standard of care, first-line treatment for adults with RRP. Long-term clinical data presented at major conferences demonstrate durable complete responses and highlight the substantial healthcare burden of RRP.
- Pipeline Progress: Precigen continues development of PRGN-2009 AdenoVerse® Immunotherapy for HPV-associated cancers, with multiple phase 2 trials ongoing in partnership with the National Cancer Institute.
Financial Performance and Outlook
- Revenue Growth: Total revenues for 2025 increased \$5.8 million year-over-year, boosted by the launch of PAPZIMEOS and higher collaboration/licensing income.
- Cash Position: Cash, cash equivalents, and investments totaled \$100.4 million as of December 31, 2025, expected to fund operations through cash flow break-even by year-end 2026.
- Cost Structure: Research and development expenses decreased by \$11.7 million (22.1%), reflecting the strategic prioritization of the pipeline and the closure of ActoBio operations. SG&A expenses increased \$28.8 million (69.8%) due to commercial readiness and launch costs for PAPZIMEOS, including sales force expansion and marketing.
- Impairments & Non-cash Charges: The company recorded \$3.9 million in impairment charges in 2025 related to Exemplar, down from \$5.8 million in 2024. In 2024, \$34.5 million in impairment was recorded due to the ActoBio closure.
- Warrant Liability Impact: Total other income (expense) swung from a net income of \$7.0 million in 2024 to a net expense of \$140.1 million in 2025, primarily due to a \$139.5 million increase in the fair value of warrant liabilities prior to their reclassification to equity, driven by a rise in Precigen’s stock price.
- Deemed Dividend: A substantial \$179.0 million non-cash deemed dividend on preferred stock was recorded in Q3 2025, impacting net loss per share calculations. All preferred shares were converted into common shares as of September 15, 2025.
- Net Loss: Net loss attributable to common shareholders was \$429.6 million (\$1.37 per share) for 2025, compared to \$126.2 million (\$0.47 per share) in 2024. The increase was mostly due to the non-cash warrant liability and deemed dividend charges.
Balance Sheet Overview (as of December 31, 2025)
- Total assets: \$155.5 million
- Current assets: \$115.2 million
- Long-term debt: \$93.2 million (new in 2025)
- Shareholders’ equity: \$20.9 million (down from \$38.5 million in 2024)
- Warrant liabilities: Eliminated in 2025 (were \$50.5 million in 2024)
- Mezzanine equity: Eliminated in 2025 (was \$28.2 million in 2024)
Investor and Shareholder Considerations
- Commercial Success & Market Penetration: The rapid uptake of PAPZIMEOS, high physician adoption, and broad payer coverage point to robust commercial momentum, which could drive future revenue growth and positively affect share value.
- Regulatory & Reimbursement Milestones: The assignment of a permanent J-code and ongoing EMA review are significant catalysts. Successful European approval could expand the addressable market.
- Non-cash Accounting Charges: While the net loss is substantial, it is largely attributable to non-cash warrant and preferred stock charges. Investors should focus on operational cash flow and sales trajectory.
- Cash Flow Outlook: Management expects to reach cash flow break-even by the end of 2026, mitigating dilution risk and supporting longer-term value creation.
- Pipeline Advancement: Ongoing clinical trials in immuno-oncology and orphan drug designation in Europe add further optionality and potential upside.
- Consensus as Standard of Care: The endorsement of PAPZIMEOS as the first-line standard of care for RRP in adults by leading physicians is likely to increase adoption and reinforce market leadership.
Potential Price-Sensitive Events
- The acceleration of commercial sales and payer coverage for PAPZIMEOS.
- Assignment of a permanent J-code streamlining reimbursement and patient access.
- EMA review and potential European approval of PAPZIMEOS, expanding the market.
- Conversion of preferred shares to common shares, eliminating mezzanine equity and simplifying capital structure.
- Large non-cash charges (warrant liability and deemed dividend) impacting reported net loss, but not operational performance.
- Management guidance on cash flow break-even and funding runway through 2026.
- Expert consensus endorsement solidifying PAPZIMEOS as the new standard of care.
- Ongoing clinical and pipeline progress in HPV-associated cancers and other indications.
Conference Call
Precigen will host a conference call at 4:30 PM ET to discuss full year 2025 financial results and provide further updates on commercial progress for Q1 2026.
Contact Information
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. Investors should review Precigen’s most recent SEC filings and consult their financial advisors before making any investment decisions.
View PRECIGEN, INC. Historical chart here
